Institutional members access full text with Ovid®

Share this article on:

Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refractory Pediatric Sarcomas

Hingorani, Pooja MD; Eshun, Francis MD; White-Collins, Andrea PNP; Watanabe, Masayo MD

Journal of Pediatric Hematology/Oncology: October 2012 - Volume 34 - Issue 7 - p 524–527
doi: 10.1097/MPH.0b013e31826b9d25
Clinical and Laboratory Observations

Background: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients.

Observations: We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months.

Conclusions: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.

Divisions of Hematology and Oncology, Phoenix Children's Hospital, Phoenix, AZ

The authors declare no conflict of interest.

Reprints: Pooja Hingorani, MD, Phoenix Children’s Hospital, 1919 E Thomas Road, Phoenix, AZ 85016 (e-mail:

Received January 12, 2011

Accepted March 27, 2012

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.